A small, foreign-based biotech company realizes that filling clinical trials will be completed sooner, saving millions of dollars, if the vocal patient community who could benefit from the product supports were educated about the need for it.
WHITECOAT worked within regulatory guidelines to establish a community advisory board (CAB) to engage patients by offering a regular dialogue with Company management.
Patient advocates are meeting with Members of Congress to demand more research funding that would benefit the Company. Government researchers are hearing about the potential product from patient advocates who are demanding that federal resources be allocated to expedite the study of the safety and efficacy of the product. Social networking “home bases” have been created and are being fed regular updates from the patient advocates and to the patient advocates. The CAB also generated news stories and boosted clinical trial recruitment numbers.
